Biotech Values

[iwfal]

RNA / BMRN:

Did anyone else (besides me) find it interesting that BMRN acquired all of RNA rather then work out some sort of licensing deal? From the call it was pretty clear that BMRN's interest at this time was only in acquiring Drisapersen.

As I noted on twitter the size of the deal for a non-competitive technology (inherent toxicity) implies to me that:

1) this is as much a play on SRPT's drug not being approved near term as RNA's drug receiving approval - since SRPT would clearly get 90 percent of the market with lesser AE (and fact that patient parents don't care about uncertainty of proof)

2) doing some kind of deal with Sarepta is contemplated. Patents obviously. But also may involve data sharing etc.. Otherwise the RNA product has a significant risk of limited life, and it would be hard to make return on the $ spent on the acquisition in 3 or 4 years